AbbVie Inc (ABBV)vsCareDx Inc (CDNA)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
CDNA
CareDx Inc
$79.81
-1.68%
HEALTHCARE · Cap: $4.59B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 13172% more annual revenue ($66.01B vs $497.40M). CDNA leads profitability with a 25.9% profit margin vs 15.7%. CDNA trades at a lower P/E of 36.9x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
CDNA
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Margin of Safety
+70.0%
Fair Value
$65.83
Current Price
$79.81
$13.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 39.3% year-over-year
Earnings expanding 1067.0% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 9.0x book value
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 25.9% and operating margin at 8.5%. Revenue growth of 39.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, Price/Book, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while CDNA is a growth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.38 — expect wider price swings.
CDNA is growing revenue faster at 39.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 60/100), backed by strong 15.7% margins and 10.3% revenue growth. CDNA offers better value entry with a 70.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?